Alkermes Financial Statements From 2010 to 2025
| ALKS Stock | USD 27.15 0.04 0.15% |
Check Alkermes Plc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alkermes Plc's main balance sheet or income statement drivers, such as , as well as many indicators such as . Alkermes financial statements analysis is a perfect complement when working with Alkermes Plc Valuation or Volatility modules.
Check out the analysis of Alkermes Plc Correlation against competitors. Alkermes Plc Company Current Valuation Analysis
Alkermes Plc's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alkermes Plc Current Valuation | 3.77 B |
Most of Alkermes Plc's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alkermes Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Alkermes Plc has a Current Valuation of 3.77 B. This is 73.72% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 77.3% higher than that of the company.
Alkermes Plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alkermes Plc's current stock value. Our valuation model uses many indicators to compare Alkermes Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alkermes Plc competition to find correlations between indicators driving Alkermes Plc's intrinsic value. More Info.Alkermes Plc is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Alkermes Plc is roughly 2.22 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Alkermes Plc by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Alkermes Plc Financial Statements
Alkermes Plc shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Alkermes Plc investors may analyze each financial statement separately, they are all interrelated. The changes in Alkermes Plc's assets and liabilities, for example, are also reflected in the revenues and expenses on on Alkermes Plc's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Alkermes Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2211 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.